News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CyDex, Inc. Licenses Captisol(R) to Sunesis Pharmaceuticals, Inc. (SNSS) for Oncology Drug Candidate



5/3/2007 12:20:17 PM

LENEXA, Kan.--(BUSINESS WIRE)--CyDex, Inc., a specialty pharmaceutical company developing improved products through innovative drug delivery, today announced an agreement licensing its Captisol® enabling technology to Sunesis Pharmaceuticals, Inc. for formulation of a selective Aurora kinase inhibitor with potent anti-tumor activity across a number of nonclinical human cancer models.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES